Cipla and Kemwell announce joint venture for biosimilars

The venture will leverage the companies’ combined strengths in product development, clinical development, regulatory filings, manufacturing and commercialisation

Global pharmaceutical company Cipla and biopharma CDMO Kemwell Biopharma have announced a joint venture agreement to develop, manufacture and commercialise biosimilars for global markets. As part of the agreement, a joint venture company will be incorporated with the aim of entering the respiratory biosimilars space.

The venture will leverage the companies’ combined strengths in product development, clinical development, regulatory filings, manufacturing and commercialisation of biopharmceutical products. Cipla’s respiratory experience and Kemwell’s expertise in biologics are hoped to accelerate the time to market for the planned products.

Umang Vohra, MD & Global CEO of Cipla, said: “This development reinforces our strength as leaders in respiratory therapy and is in line with our aspiration of global lung leadership. Guided by our purpose of ‘Caring for life’ our partnership with Kemwell will help serve unmet needs of patients across the globe.”

Anurag Bagaria, Chair and CEO of Kemwell, said: “We are very excited about combining the strengths of Cipla’s expertise in development and commercialisation of respiratory products and Kemwell’s biologics capabilities. Through this JV, we aim to make cost-effective biotherapeutics available to more patients globally.”

Companies